Search clinical trials for: CNF2024 trastuzumab

Total 1155 results

Biogen

Completed

CNF2024 (BIIB021) HER2- (QD) HER2+ (BIW w/Herceptin) PK/PD Study

Breast Cancer

United States
Biogen

Completed

Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States
Biogen

Terminated

Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL

B-Cell Chronic Lymphocytic Leukemia

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

A Clinical Study on Hormone Receptor Positive HER2 Positive Breast Cancer of RCB1-2 After Neoadjuvant Treatment With Trastuzumab Combined With Parezumab

HER2-positive Breast Cancer | Early-stage Breast Cancer | Adjuvant Treatment After Trastuzumab | RCB Classification 1-2 | Neratini

China
Samsung Bioepis Co., Ltd.

Completed

A Study to Compare the Effect of SB3 and Herceptin® in Women With HER2 Positive Breast Cancer

HER2 Positive Early or Locally Advanced Breast Cancer

Czechia
Biogen

Completed

An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST)

GIST

United States
Biogen

Completed

Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors

Lymphoma | Tumors

United Kingdom, United States
Pfizer

Completed

A Pharmacokinetic Study Comparing PF-05280014 And Trastuzumab In Healthy Male Volunteers (REFLECTIONS B327-01)

Healthy

United States
Curon Biopharmaceutical (Australia) Co Pty Ltd
Novotech (Australia) Pty Limited

Not yet recruiting

A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies

Metastatic Solid Tumor | Hematologic Malignancies | Locally Advanced Solid Tumor
Jonsson Comprehensive Cancer Center

Completed

Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer

Breast Cancer

United States
Henan Cancer Hospital

Recruiting

Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC

Breast Cancer | HER2-positive Breast Cancer

China
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy

Breast Ductal Carcinoma In Situ

United States, Canada, Puerto Rico, Korea, Republic of
Tanvex BioPharma USA, Inc.

Completed

Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03

Breast Cancer | Breast Neoplasms | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Early-stage Breast Cancer

Belarus, Chile, Georgia, Hungary, India, Mexico, Peru, Philippines, Russian Federation, Ukraine
Spanish Breast Cancer Research Group

Completed

Phase III to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast Cancer (ChangHER-SC)

Breast Cancer

Spain
Fudan University
Hoffmann-La Roche

Unknown

Efficacy and Safety Study of Trastuzumab, Paclitaxel and Carboplatin on HER2+ Preoperative Breast Cancer (PCH)

Breast Cancer

China
Orano Med LLC

Completed

Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy

Stomach Neoplasms | Breast Neoplasms | Pancreatic Neoplasms | Ovarian Neoplasms | Peritoneal Neoplasms

United States
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

Male Breast Carcinoma | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7

United States, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
Fudan University

Completed

Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab

Breast Cancer

China
Samsung Bioepis Co., Ltd.

Terminated

A Long-term Follow-up Study for Cardiac Safety in the Patients With HER2 (+) Breast Cancer Who Have Completed the SB3-G31-BC

Breast Neoplasms

Ukraine, Romania, Russian Federation, France, Bulgaria, Czechia, Poland
University Medical Center Groningen

Completed

89Zr-trastuzumab PET for Imaging the Effect of HSP90 Inhibition (AUY922)

Breast Cancer

Netherlands
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) for Recurrent, Metastatic, or Unresectable HER2-Positive Salivary Gland Cancer

Recurrent Salivary Gland Carcinoma | Stage III Major Salivary Gland Cancer AJCC v8 | Stage IV Major Salivary Gland Cancer AJCC v8 | Metastatic Salivary Gland Carcinoma | Unresectable Salivary Gland Carcinoma

United States
Byondis B.V.

Completed

SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma

Endometrial Cancer

Korea, Republic of, Singapore, Russian Federation, Ukraine, United States, Poland, Serbia
National Cancer Institute (NCI)

Terminated

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Breast Carcinoma | HER2-Positive Breast Carcinoma

United States
AstraZeneca
Daiichi Sankyo

Completed

A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer (DESTINY-B12)

Breast Cancer

Denmark, Finland, Italy, Norway, Spain, Sweden, Poland, United States, Canada, Germany, Japan, Netherlands, Portugal, Switzerland, Australia, United Kingdom, Belgium, Ireland
Pfizer

Completed

A Study Evaluating The Safety Of PF-05280014 And Trastuzumab In Healthy Male Volunteers (REFLECTIONS B327-06)

Healthy

United States
Jules Bordet Institute
Hoffmann-La Roche; Breast International Group; Institut Curie; International Drug...

Suspended

De-escalation Adjuvant Chemo in HER2+/ER-/Node-neg Early BC Patients Who Achieved pCR After Neoadjuvant Chemo & Dual HER2 Blockade (Decrescendo)

HER2-positive Breast Cancer | ER-Negative Breast Cancer | PR-Negative Breast Cancer | Node-negative Breast Cancer

Korea, Republic of, France, Israel, Belgium, Switzerland, Australia
Fujian Medical University Union Hospital

Recruiting

Compare Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast Cancer

Breast Cancer | Adjuvant Therapy

China
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors

Sarcoma | Breast Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer | Unspecified Adult Solid Tumor, Protocol Specific

United States
Shanghai Henlius Biotech

Completed

A Safety and Pharmacokinetic Study Between HLX02 and Herceptin®(US-licensed and EU-approved) in Healthy Chinese Male Subjects

Healthy

China
Shen Lin

Unknown

Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System

Colorectal Cancer | Esophageal Squamous Cell Carcinoma | Biliary Tract Cancer | Targeted Therapy | HER2

China
Nanogen Pharmaceutical Biotechnology Joint Stock...
Vietstar Biomedical Research; MedProve Inc

Completed

Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients

Breast Cancer Recurrent | Breast Cancer Female | Breast Cancer Metastatic

Vietnam
Nanogen Pharmaceutical Biotechnology Joint Stock...
Vietstar Biomedical Research; MedProve Inc

Completed

Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients.

Breast Cancer Recurrent | Breast Cancer Female | Breast Cancer Metastatic

Vietnam
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Withdrawn

T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | HER2 Positive Breast Carcinoma | Metastatic Breast Carcinoma

United States
Washington University School of Medicine
Molecular Templates, Inc.

Withdrawn

89Zr-Trastuzumab PET/CT in Subjects With Previously Treated HER2-Positive Solid Tumors Scheduled to Receive Treatment With MT-5111

HER2-positive Solid Tumor | HER-2 Positive Cancer
Hoffmann-La Roche

Completed

A Study of Cardiac Safety in Patients With HER2 Positive Early Breast Cancer Treated With Herceptin

Breast Cancer

Italy, Austria, Belgium, Germany, Spain, United Kingdom, Hungary, Poland, Sweden
Hoffmann-La Roche

Terminated

A Study of Herceptin (Trastuzumab) in Combination With Standard Chemotherapy in Patients With HER Positive Metastatic Gastric Cancer

Gastric Cancer

India
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Trastuzumab in Treating Patients With Prostate Cancer

Prostate Cancer

United States
Regione Lombardia
Mario Negri Institute for Pharmacological Research; Istituto Clinico Humanitas

Unknown

Trastuzumab Optimization Trial in Breast Cancer (TOP)

Metastatic or Locally Advanced Breast Cancer

Italy
Fudan University

Not yet recruiting

T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low Patients

Triple-Negative Breast Cancer

China
Yale University
Genentech, Inc.

Withdrawn

Evaluation of Trastuzumab In Patients With HER2 Positive Persistent Or Recurrent Vulvar Paget's Disease

Paget's Disease of the Vulva

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

Trastuzumab in Treating Patients With Locally Advanced or Metastatic Synovial Sarcoma

Sarcoma
Daiichi Sankyo, Inc.
AstraZeneca

Recruiting

Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

Breast Cancer

United States
Peking University Cancer Hospital & Institute

Not yet recruiting

Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast Cancer

Breast Neoplasm Female
European Organisation for Research and Treatment...
Hoffmann-La Roche

Completed

Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1

Elderly Metastatic Breast Cancer Population

Belgium, Italy, Netherlands, France, Poland, United Kingdom, Portugal, Sweden
National Cancer Institute (NCI)
NRG Oncology

Completed

Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer

Esophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Stage IIA Esophageal Cancer AJCC v7 | Stage IIB Esophageal Cancer AJCC v7 | Stage IIIA Esophageal Cancer AJCC v7 | Stage IIIB Esophageal Cancer AJCC v7 | Stage IB Esophageal Cancer AJCC v7

United States
University of Washington
National Cancer Institute (NCI)

Completed

Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by Surgery

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | HER2/Neu Positive

United States
Hoffmann-La Roche

Completed

THOR Study: A Study of Continued Herceptin (Trastuzumab) in Combination With Second Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.

Breast Cancer

Italy
University of Michigan Rogel Cancer Center

Terminated

Use of Trastuzumab to Induce Increased ER Expression in ER-negative/Low, Her-2/Neu Positive Breast Cancer

Breast Cancer

United States
Fudan University

Recruiting

Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab

Metastatic Breast Cancer | HER2-positive Breast Cancer

China

Search clinical trials for: CNF2024 trastuzumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Chile

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations